NEW YORK (GenomeWeb News) – Diagnoplex and Debiopharm Diagnostics, part of the Debiopharm Group, today announced that Diagnoplex has secured CHF1.3 million ($1.4 million) in financing.

Debiopharm led the round, while Neomed and Capital Romandie also participated in the financing.

Diagnoplex will use the funds to support its efforts to obtain CE marking for Colox, a non-invasive, blood-based test for the early detection of colorectal cancer. The Lausanne, Switzerland-based firm also hopes to prepare a comparative clinical trial for Colox.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.